|

Cyclophosphamide (primary intervention for GVHD prophylaxis) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Mycophenolate mofetil (MMF) (part of the GVHD prophylaxis regimen), Tacrolimus (part of the GVHD prophylaxis regimen)

Pipeline

Phase 2: 1

Top Sponsors

  • Milton S. Hershey Medical Center1

Indications

  • Graft-versus-Host Disease (GVHD)1
  • Allogeneic Stem Cell Transplantation1
  • Hematologic Malignancies1
  • Cancer1

Hershey, Pennsylvania1 trial

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

Penn State Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.